Ocugen
The Qualified Person for Pharmacovigilance (QPPV) is responsible for establishing and maintaining a compliant European pharmacovigilance system to support clinical development, regulatory submissions, and future commercialization. This role ensures adherence to EMA Good Pharmacovigilance Practices (GVP), manages safety reporting processes, and partners with cross-functional teams to integrate patient safety throughout the product lifecycle. The position involves developing scalable pharmacovigilance capabilities and providing expert guidance on European safety requirements.
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ocugen.
Ocugen didn’t post a salary, so this is our estimate from similar listings.
Associate Director, Deputy QPPV
Revolution Medicines
Senior Director, Qualified Person for Pharmacovigilance, Europe
Revolution Medicines
Senior Pharmacovigilance Manager
Cytokinetics
Manager, Global Patient Safety - QPPV Governance
Regeneron Pharmaceuticals
Senior Pharmacovigilance Manager, QPPV Office
ProPharma
Senior Director, Qualified Person for Pharmacovigilance, Europe
Revolution Medicines